The aim of this study was to investigate whether the S100B polymorphisms are
associated with systemic lupus erythematous (SLE) in a Chinese population. A
total of 313 SLE patients and 396 control subjects were enrolled in the present
study. The genotypes of three SNPs (rs9722, rs881827 and rs1051169) in S100B
gene were detected by single base extension polymerase chain reaction (SBE-PCR).
Serum S100B levels were determined by enzyme-linked immunosorbent assay (ELISA).
Rs1051169 was associated with an increased risk of SLE (C vs. G: adjusted
OR=1.46, 95% CI, 1.18-1.80,
p
=0.001; CC vs. GG: adjusted
OR=1.99, 95% CI, 1.32-3.02,
p
=0.001; CC+GC vs. GG: adjusted
OR=1.54, 95% CI, 1.13-2.11,
p
=0.007; CC vs. GC+GG: adjusted
OR=1.67, 95% CI, 1.16-2.42,
p
=0.006). Haplotype analysis showed
that the G-G-C haplotype was associated with an increased risk of SLE (OR=1.50,
95% CI, 1.14-1.98,
p
=0.004). Stratified analyses showed that
the rs1051169 polymorphism was associated with an increased risk of neurologic
disorder in SLE patients (C vs. G: OR=1.78, 95% CI, 1.22-2.59,
p
=0.003; GC vs. GG: OR=2.33, 95% CI, 1.14-4.77, P=0.019; CC
vs. GG: OR=3.02, 95% CI, 1.39-6.53,
p
=0.004; CC+GC vs. GG:
OR=2.57, 95% CI=1.31-5.04,
p
=0.005). In addition, SLE patients
with neurologic disorder carrying the rs1051169 GC/CC genotypes present a higher
serum S100B levels compared with that carrying the GG genotype
(
p
< 0.05). Our results indicate that the rs1051169
polymorphism may be involved in the pathogenesis of SLE.